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Abstract 
Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant 
to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has 
been widely practiced and gives varying results 
Objective: Our objective was to compare the efficacy of Sebclair® and topical hydrocortisone 2,5% for 
management of moderate SD on the face 
Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We 
assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using 
Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual 
Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. 
Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. 
The mean of SASI T2 and VAS score of the Sebclair® group was significantly lower than Hydrocortisone 2.5% 
group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclair® and Hydrocortisone 2.5% 
showed insignificant results (p = 1.000) 
Conclusions: The longer application of Sebclair® was significantly more effective to improve moderate SD 
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1 INTRODUCTION 
Seborrhoeic dermatitis (SD) is a chronic papulosquamosa inflammatory disease 
characterised by exacerbation, remission periods and resistant to medical treatment. It occurs 
in immunocompetent adult in 5% range of the entire population, generally 30-60 years old.1,2 
Although its prevalence is small, but 34 - 83% of SD occur in immunocompromised patients 
with risk factors. Recently, at least 50% of HIV patients have been encountered with SD.3,4 
Its also found in patients with Parkinson disease or patients receiving treatment such as 
haloperidol decanoate, buspirone, chlorpromazine.4 The prevalence of SD in adults is higher, 
especially in the age range of 30-60 years old.5 Various risk factors increase the clinical 
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severity of SD, it comorbidities with systemic disease such as diabetes mellitus, 
hypertension, Parkinson's disease, HIV infection, environmental conditions such as air-
conditioned room, resulting in persistent and exacerbation. Until now, its pathogenesis is still 
unclear, factors associated with SD are Malassezia spp., skin surface lipid film (SSLF), 
sebaceous gland activity, and excess sebum production.6,7 Some experts think excess sebum 
production is not a risk factor associated with SD. Other factors related to SD pathogenesis 
include immune responses, individual susceptibility, and neurogenic.8 It factors resulting in 
impaired skin function and skin barrier thus increased host vulnerability.9  
Seborrhoeic dermatitis appears in the area which contains many sebaceous glands, 
especially on face, nasal folds, central part of the face, eyebrows, head, chest and back, with 
a typical features of patches erythematous, oily and white-yellowish scale, smooth, 
accompanied by itch.10  
Seborrhoeic dermatitis clinical severity assessed using score of Seborrhea Area Severity 
Index-Facial (SASI-F). SASI-F score is obtained by assessing the area involved, 
erythematous, scale, and face area involvement. The clinical severity score obtained after the 
calculation. The head area is divided into areas of scalp and face (including neck and ears), 
given equal weight for the purpose of calculating engagement score divided into 6 scores (0 
= less than 1% ; 1 = 1 - 10%; 2 = 11-20%, 3 = 21-35%, 4 = 36- 50%, 5 = 51-75%; 6 = 76-
100%).3 Pruritus was assessed by VAS with a range 0 until 10 
The treatment aims to decrease inflammation; reduce erythematous, scale, itching and 
prevention of exacerbation. Various SD treatment on the face has been widely practiced and 
gives varying results.2 Topical treatment is the first choice in moderate SD, including 
corticosteroids (CS) such as 2.5% hydrocortisone. Topical CS cannot be given in the long 
term period because it causes skin atrophy and telangiectasis. Other topical treatments are 
2% ketoconazole cream and tacrolimus cream. The application of tacrolimus cream must be 
careful and the price is quiet expensive.11  
Sebclair® is a new non-steroid topical drug containing 1.2% bisabolol, 0.5% pyroctone 
olamine, 1% alglycera and 0.01% telmesteine. Sebclair® has an effect such as anti-
inflammatory, anti-fungal and anti pruritus. Study by Micali (2015) in adult SD treated with 
Sebclair® for 4 weeks, double blind, with placebo as control, randomization (n = 60) 
evaluated clinical and erythematous skin by assessing IGA therapeutic results, assessing 
pruritus with VAS, showed significantly improved (decreased erythematous, scale) by 68% 
compared to placebo by 11%.12 
2 METHODS  
This was a randomised, double-blind, controlled study in adult patients with SD in the 
Dermatovenereology Outpatient Unit of General Hospital Dr. Mohammad Hoesin 
Palembang (RSMH) from June 2017 – March 2018. Inclusion criteria is patients aged ≥ 20 
years old with moderate SD on the face. Exclusion criteria are patients with light or severe 
SD, allergic to the substances used in the study, patients with other dermatoses on the face, 
patients taking oral retinoid within 6 weeks before study; patients taking antibiotics, 
immunosuppression drugs, hormones (corticosteroids), contraceptives, and other vitamins 
within 4 weeks before study; patients using topical corticosteroids or antibiotics, facial wash 
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or makeup containing antibiotic or corticosteroid ingredients within 2 weeks before study; 
patients undergoing chemical peeling, laser and other aesthetic treatments within 4 weeks 
before study; patients who are pregnant, lactating, or planning to pregnant; patients with a 
diagnosis of drug eruption or have a lot of scar tissue on the face which complicates 
investigator evaluation or evaluation using the instrument (photo). 
Informed concent was obtained from the patients. All the patients were subjected to 
history taking such as name, age, sex and occupation. The patients divided into Sebclair® 
group and hydrocortisone 2,5% group. Baseline data of SASI-F score and VAS were 
collected. Assessment of SASI-F, VAS and tolerance were collected every two weeks of 
follow up. The length of follow up duration is four weeks.  
Data then analysed by Wilcoxon test, Mann Whitney U test and Fisher exact test. Ethical 
clearance had been approved for this study by the Local Ethical Committee. 
3 RESULTS 
A total of 34 patients from two groups were examined. The results showed that female 
(20 patients; 117,6%)  are common than male in both groups (14 patients; 82,4%). Mean age 
in Sebclair® group is 31,53 ± 13,39 and mean age of hydrocortisone is 38,59 ± 14,34.   
 In the Sebclair® group, the median of VAS T0 and T1 are 3 and 2 respectively (p= 0,000). 
Median of VAS T1 with VAS T2 are 2 and 0 (p= 0,004) respectively. The median of SASI 
T0 and T1 in Sebclair® group are 3 and 2 (p=0,000) respectively, and the median of SASI T1 
and T2 are 2 and 1 (p=0,000) respectively.  
 In the hydrocortisone 2,5% group, both of median of VAS T0 and T1 are 3 (p=0,008). 
Median of VAS T1 and T2 are 3 and 2 (p=0,005) respectively. The median SASI T0 and T1 
are 3 and 2,5 respectively (p=0,000). Median SASI T1 and T2 are 2,5 and 2 (p=0,004) 
respectively.  
 Comparison of median VAS T1 in Sebclair® and Hydrocortisone 2,5% group are: 2 and 3 
(p=0,009) respectively. Median VAS T2 in Sebclair® and hydrocortisone 2,5% group are 0 
and 2 (p= 0,000) respectively. (Table.1) 
    Comparison of median SASI T1 in Sebclair® and Hydrocortisone 2,5% group are: 2 and 
2,5 (p=0,057) respectively. Median SASI T2 in Sebclair® and hydrocortisone 2,5% group are 
1 and 2 (p=0,000) respectively. (Table.2) 
 The tolerance in Sebclair® group was found in 1 patient who experienced mild irritation 
(5.9%) while in the hydrocortisone 2.5% group did not experience an irritation (p=1,000). 
 
 
 
 
Tabel 1. VAS score of Sebclair® and Hydrocortisone 2.5% in patients with Seborrhoeic  
               Dermatitis 
VAS Value Treatment p value 
Median value (min-max) 
Sebclair® 
Median value (min-max) 
Hidrokortison 2,5%  
T1   2 (0 – 3) 3 (1 – 4) 0,009 
T2 0 (0 – 2) 2 (0 – 4) 0,000 
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Table 2. SASI score of Sebclair® and Hydrocortisone 2.5% in patients with seborrhoeic  
               dermatitis 
SASI value Treatment p 
value 
Median value (min-max) 
Sebclair® 
Median value (min-max) 
Hydrocortisone 2,5%  
T1   2 (0 – 3) 2,5 (2 – 3,5) 0,057 
T2  1 (0 – 2,5) 2 (1 – 3) 0,000 
 
4 DISCUSSION  
 This study was compared Sebclair® cream with hydrocortisone cream 2.5% in patients 
with SD on face. This study assessed SASI, VAS and drug tolerance score on SD patients on 
face from March 2017 to February 2018. The sampling technique was randomised, double-
blind, and controlled. A total of 34 study subjects with a DS diagnosis who met inclusion 
criteria were included as subject. 
 Based on demographic data, the most subjects in the two treatment groups is female, as 
many as 20 patients (64.7%). This is in accordance with study by Araya, et al (2015) in 166 
patients obtained more female than men.13 Yet another literature shows different results: 
male are more likely to suffer from DS than female.14 This may be related to attention of the 
physical appearance more common in female than male, so female more often to seek the 
treatment. 
 In this study the mean age of SD subject in Sebclair® group is 31.53 ± 13.39 years old, 
whereas in Hydrocortisone 2.5% group is 38.59 ± 14.34 years old. This is in accordance with 
the average age of SD patients in the study by Oglio, et al (2015) is 30.7 years old.14 Other 
studies reported mean age of SD patients 39.2 ± 17.7 years.15  Study by Youn, et al (2016)  
 
 
 
 
reported the mean age of SD patient is 35.57 years old.16 The severity of SD decreases with 
age, but some factors such as emotional stress and less rest often associated with 
occupational factors, especially in adult patients, will trigger SD induced expulsion of pro 
inflammation   cytokines.15 
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 Sebclair® group showed a significant decrease in SASI T1 score compared to baseline 
(p = 0.000) and SASI T2 compared to T1 (p = 0,000). Decreased pruritus with VAS score 
was also significant in VAS T1 compared to baseline (p = 0.000) and decreased VAS score 
on T2 compared to VAS T1 (p = 0,004). These results are in line with study by Oglio 
showing significant changes in erythema (p = 0.0001), desquamation (p = 0.0002), and 
pruritus (p = 0.0001) compared to baseline after 28 ± 2 days.14 Sebclair® is a nonsteroid 
topical drug, containing 1.2% bisabolol, 0.5% ococheme olamine, 1% alglycera and 0.01% 
telmesteine. Bisabolol, telmesteine and alglycera work as anti-inflammatory and antipruritus 
plays a role in repairing skin barrier. Alglycera increase moisture in the extracellular matrix 
and has keratolytic effect by increasing desquamation in the corneocyte layer.14 Piroctone 
olamine, an antifungal, is capable to penetrate the fungal membranes cell and forming a 
complex ions with iron, thereby inhibiting the fungal mitochondrial metabolism.16 
In hydrocortisone 2.5% group, significant decreases were also obtained in the SASI T1 
score compared to baseline (p = 0.000) and SASI T2 compared with T1 (p = 0.004). There 
was a significant decrease in VAS T0 score compared to VAS T1 (p = 0,008) and decreased 
VAS T1 score compared to VAS T2 (p = 0,005). The application of hydrocortisone for 12 
weeks, effectively reduce SASI and VAS in 72 patients with moderate SD.1 Other studies 
have shown the effectiveness of hydrocortisone in reducing SASI and VAS in week 4 of 
application.11 Hydrocortisone works as anti-inflammatory thereby decreasing the 
proliferation of stratum corneum. This anti-inflammatory function also helps to improve the 
differentiation of corneocytes, so that increasing the skin barrier function and reduces M. 
furfur colonization in the skin.17 On the other hand, long-term use of corticosteroids can 
cause side effects such as atrophy, telangiectasis, hypertrichosis and perioral dermatitis.10 
The mean SASI T1 score was not significantly different in the two groups (p = 0.057). 
The mean score of SASI T2 in Sebclair® group was significantly lower than Hydrocortisone 
2.5% group (p = 0.000). Sebclair® group also showed a significantly lower of VAS T2 than 
Hydrocortisone 2.5% group (p = 0.000). The results showed that the efficacy of Sebclair® in 
a short duration did not differ significantly with hydrocortisone, but Sebclair® group was 
significantly more effective (p = 0.000) after longer usage. There have been no case reported 
the efficacy of Sebclair® compared to Hydrocortisone 2.5%, but combination of active 
ingredient in Sebclair® may lead to better effectiveness in long-term treatment of SD. 
Tolerance between Sebclair® and Hydrocortisone 2.5% of SD patients gave 
insignificant results (p = 1.000), although there was 1 patient with mild irritation to Sebclair® 
application. There have been few reports of Sebclair® side effects, but one study by Veraldi, 
et al (2008) reported 4 patients experiencing adverse effects of light erythema and slight 
burning.18 Some of Sebclair® side effects include erythema, burning, itching and edema.18  
5 CONCLUSION 
It can be concluded that Hydrocortisone 2.5% and Sebclair® have the same 
effectiveness in short-term of DS treatment. Sebclair® is consider more superior than 
hydrocortisone 2,5% if the duration of application is longer. The application of long-term 
hydrocortisone 2.5% should be avoided to prevent side effects such as atrophy, 
telangiectasis, hypertrichosis and perioral dermatitis. Sebclair® may be considered as an 
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alternative therapy for both short and long term of DS treatment. 
 
 
6 LIMITATION 
 This study has a limitation such as small sample size and short term of follow-up. 
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